Essex Investment Management Co. LLC lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,760 shares of the company's stock after selling 29,396 shares during the quarter. Essex Investment Management Co. LLC owned 0.21% of Tarsus Pharmaceuticals worth $4,416,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Lisanti Capital Growth LLC increased its stake in shares of Tarsus Pharmaceuticals by 143.3% during the 4th quarter. Lisanti Capital Growth LLC now owns 96,935 shares of the company's stock worth $5,367,000 after purchasing an additional 57,090 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth $1,107,000. Aigen Investment Management LP purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth $415,000. Victory Capital Management Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth $223,000. Finally, Keybank National Association OH lifted its position in shares of Tarsus Pharmaceuticals by 24.1% in the fourth quarter. Keybank National Association OH now owns 12,383 shares of the company's stock valued at $686,000 after acquiring an additional 2,404 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently commented on TARS. Guggenheim reiterated a "buy" rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Finally, Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $63.67.
Read Our Latest Stock Report on TARS
Tarsus Pharmaceuticals Trading Down 1.3 %
Shares of NASDAQ:TARS traded down $0.63 during trading on Thursday, reaching $46.47. 1,087,520 shares of the stock were exchanged, compared to its average volume of 640,294. The firm's 50-day moving average price is $49.44 and its 200 day moving average price is $44.31. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -12.20 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.
About Tarsus Pharmaceuticals
(
Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
